ArticleAddiction biology2017
Kappa opioid receptor antagonism and chronic antidepressant treatment have beneficial activities on social interactions and grooming deficits during heroin abstinence.
Article in Addiction biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Kappa opioid receptor antagonism in neuropsychiatry: from molecular mechanisms to clinical prospects.European archives of psychiatry and clinical neuroscience · 2026Review
- Mu or delta opioid receptor antagonists increase the expression of social conditioned place preference in early adolescent mice.Psychopharmacology · 2026Article
- Disrupted maternal behavior in morphine-dependent pregnant rats and anhedonia in their offspring.Neuropharmacology · 2025Article
- Emerging medications and pharmacological treatment approaches for substance use disorders.Pharmacology, biochemistry, and behavior · 2025Review
- Incubation of social deficit during morphine abstinence in male mice using a novel unbiased and automatized method.Frontiers in behavioral neuroscience · 2025Article
- The Dynorphin/-Opioid Receptor System at the Interface of Hyperalgesia/Hyperkatifeia and Addiction.Current addiction reports · 2025Review
- Zona incerta: from Parkinson's disease to addiction.Frontiers in neural circuits · 2025Article
- Disrupted Maternal Behavior in Morphine-Dependent Pregnant Rats and Anhedonia in their Offspring.bioRxiv : the preprint server for biology · 2024Article
- Chronic Morphine Leaves a Durable Fingerprint on Whole-Brain Functional Connectivity.Biological psychiatry · 2024Article
- Model of negative affect induced by withdrawal from acute and chronic morphine administration in male mice.Scientific reports · 2024Article
- Opioidergic tuning of social attachment: reciprocal relationship between social deprivation and opioid abuse.Frontiers in neuroanatomy · 2024Review
- Mu Opioid Receptor-Expressing Neurons in the Dorsal Raphe Nucleus Are Involved in Reward Processing and Affective Behaviors.Biological psychiatry · 2023Article
- Mu Opioid Receptor-Positive Neurons in the Dorsal Raphe Nucleus Are Impaired by Morphine Abstinence.Biological psychiatry · 2023Article
- Advances in the characterization of negative affect caused by acute and protracted opioid withdrawal using animal models.Neuropharmacology · 2023Review
- Upregulation of dynorphin/kappa opioid receptor system in the dorsal hippocampus contributes to morphine withdrawal-induced place aversion.Acta pharmacologica Sinica · 2023Article
- Modulation of 5-HT release by dynorphin mediates social deficits during opioid withdrawal.Neuron · 2022Article
- Suboxone: History, controversy, and open questions.Frontiers in psychiatry · 2022Review
- C57BL/6N mice show a sub-strain specific resistance to the psychotomimetic effects of ketamine.Frontiers in behavioral neuroscience · 2022Article
- Friend of the Devil: Negative Social Influences Driving Substance Use Disorders.Frontiers in behavioral neuroscience · 2022Review
- Kappa Opioid Receptor Antagonists as Potential Therapeutics for Mood and Substance Use Disorders.Handbook of experimental pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Addiction is a chronic brain disorder that progressively invades all aspects of personal life. Accordingly, addiction to opiates severely impairs interpersonal relationships, and the resulting social isolation strongly contributes to the severity and chronicity of the disease. Uncovering new therapeutic strategies that address this aspect of addiction is therefore of great clinical relevance. We recently established a mouse model of heroin addiction in which, following chronic heroin exposure, 'abstinent' mice progressively develop a strong and long-lasting social avoidance phenotype. Here, we explored and compared the efficacy of two pharmacological interventions in this mouse model. Because clinical studies indicate some efficacy of antidepressants on emotional dysfunction associated with addiction, we first used a chronic 4-week treatment with the serotonergic antidepressant fluoxetine, as a reference. In addition, considering prodepressant effects recently associated with kappa opioid receptor signaling, we also investigated the kappa opioid receptor antagonist norbinaltorphimine (norBNI). Finally, we assessed whether fluoxetine and norBNI could reverse abstinence-induced social avoidance after it has established. Altogether, our results show that two interspaced norBNI administrations are sufficient both to prevent and to reverse social impairment in heroin abstinent animals. Therefore, kappa opioid receptor antagonism may represent a useful approach to alleviate social dysfunction in addicted individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.